Guideline for cervical cancer screening in Spain, 2014;Guía de cribado del cáncer de cuello de útero en España, 2014

Progresos de Obstetricia y Ginecologia

Volumn 57, Issue , 2014, Pages 1-53

  Bladé, Aureli Torné ^a   Saladrigues, Marta del Pino ^b   Gimferrer, Maite Cusidó ^c   Quitllet, Francesc Alameda ^d   Ortiz, Daniel Andia ^e   Piqué, Xavier Castellsagué ^c   Bordoy, Javier Cortés ^f   Carreño, Rosario Granados ^g   Guarch Troyas, Rosa María ^h   Rubio, Belén LLoveras ⁱ   Rosales, Amina Lubrano ^j   Martínez Escoriza, Juan Carlos ^k   Majà, Jaume Ordi ^l   Puig Tintoré, Luis M ^m   Mena, Mar Ramírez ⁿ   Llongueras, Silvia de Sanjosé ^o   Cardoso, Rafael Torrejón ^p   José, Xavier Bosch ^c,q   Piris Pinilla, Miguel Ángel ^r,s   Costa, Julio Rodríguez ^t,u   Delgado, Rafael Comino ^v,w   Lailla Vicens, Josep M ^c,x   Sebastià, Jordi Ponce ^c,y   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f Ginecología Oncológica   (Spain)

^g HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^h UNIVERSITY OF NAVARRA   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^o BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^p UNIVERSITY OF CÁDIZ   (Spain)

^q Institut Catal d'Oncologia (ICO)   (Spain)

^r HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^s Sociedad Española de Anatomía Patológica SEAP   (Spain)

^t HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^u Sociedad Española de Citología SEC   (Spain)

^v UNIVERSITY OF CÁDIZ   (Spain)

^w Asociación Española de Patología Cervical y Colposcopia AEPCC   (Spain)

^x Sociedad Española de Ginecología y Obstetricia SEGO   (Spain)

^y Sección de Ginecología Oncológica y Patología Mamaria de la SEGO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; PRACTICE GUIDELINE; SPAIN; TREND STUDY; UTERINE CERVIX CANCER;

EID: 84956587139     PISSN: 03045013     EISSN: 15781453     Source Type: Journal    
DOI: 10.1016/S0304-5013(14)73068-7     Document Type: Article

References (228)

1. Puig-Tintoré LM, Cortés J, Castellsagué X, Torné A, Ordi J, de San José S, et al. Prevención del cáncer de cuello uterino ante la vacunación frente al virus del papiloma humano. Prog Obstet Ginecol. 2006;46:5-62.
2. Instituto Nacional de Estadística, 2013a. Cifras de población a 1 de enero de 2013. Resultados nacionales. Población residente por fecha, sexo y edad. Disponible en: http://www.ine.es/jaxi/tabla.do?path=/t20/p321/serie/l0/&file=01001.px&type=pcaxis&L=0
3. De Sanjosé S, Cortés X, Méndez C, Puig-Tintore L, Torne A, Roura E, et al. Age at sexual initiation and number of sexual partners in the female Spanish population. Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol. 2008;140:234-40.
4. Instituto Nacional de Estadística, 2013b. Encuesta Nacional de Salud 2011-2012. Ficheros de microdatos. Disponible en: http://www.ine.es/prodyser/micro_ensalud.htm. (Consultado 22-10-2014).
5. Castellsague X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, et al. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. J Med Virol. 2012;84:947-56.
6. Rodríguez-Salés V, Roura E, Ibáñez R, Peris M, Bosch FX, de San José S. Coverage of cervical cancer screening in Catalonia for the period 2008-2011 among immigrants and Spanish-born women. Front Oncol. 2013;3:297.
7. Castellsague X, Remy V, Puig-Tintore LM, de la Cuesta RS, González-Rojas N, Cohet C. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain. J Low Genit Tract Dis. 2009;13:38-45.
8. Izquierdo A, Marcos-Gragera R, Vilardell L, Buxó M, Fuentes J. El càncer a Girona 2005-2006. Can Gir. 2005-6. 2012;3.
9. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403.
10. Consejo Interterritorial del Sistema Nacional de Salud. Detección precoz del cáncer de cuello de útero. Estrategia en Cáncer del Sistema Nacional de Salud. 2009; p. 114-5.
11. Disponible en: http://www.juntadeandalucia.es/servicioandaluzdesalud/principal/documentosacc.asp?pagina=gr_cartera2008&file=/contenidos/gestioncalidad/CarteraServicios/CarteraServicios2008/html%5CA1_2_3_2.htm. (Consultado 21-9-2013).
12. Gobierno de Aragón. Servicio Aragonés de Salud. Manual de Uso de los Planes Personales Centrales. Dirección de Atención Primaria SALUD. Servicio 206: Diagnóstico Precoz del Cáncer de Cérvix. 2010.
13. Disponible en: www.asturias.es/Astursalud/Ficheros/AS_Salud%20Publica/AS_Salud%20Poblacional/C%C3%A1ncer%20de%20C%C3%A9rvix/cuello_utero09.pdf. (Consultado 21-9-2013).
14. Consellería de Salut i Consum.Govern de les Illes Balears. Programa de Prevención del Cáncer de Cérvix. 2004.
15. Disponible en: http://www2.gobiernodecanarias.org/sanidad/scs/content/c140a779-960c-11-2-8322-abfbca94030c/N3_Cuello_utero.pdf. (Consultado 26-9-2013).
16. Disponible en: http://www.saludcantabria.es/uploads/pdf/profesionales/PROTOCOLO%20CANCER%20CUELLO%20DE%20UTERO%20(28-3-11).pdf. (Consultado 21-9-2013).
17. Disponible en: http://sescam.jccm.es/web1/profesionales/AtencionPrimaria/PROGRAMA_DE_PREVENCION_DE_CANCER_DE_CERVIX.pdf. (Consultado 21-9-2013).
18. Disponible en: www.saludcastillayleon.es/ciudadanos/es/salud-estilos-vida/prevencion-cancer/deteccion-cancercuello-utero. (Consultado 21-9-2013).
19. Ibáñez R, Moreno-Crespi J, Sardà M, Autonell J, Fibla M, Gutiérrez C, et al. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain. BMC Infect Dis. 2012;12:25.
20. Disponible en: http://blog.cuidatecv.es/2011/02/23/elcancer-de-cervix. (Consultado 20-9-2013).
21. Disponible en: http://www.orcpex.es/documentos/planes/plan_cancer_ext.pdf. (Consultado 21-9-2013).
22. Disponible en: http://www.riojasalud.es/noticias/3310-23620-riojanas-participaron-en-programas-de-deteccionprecoz-de-cancer?start=1. (Consultado 21-9-2013).
23. Disponible en: http://gdtmujersomamfyc.files.wordpress.com/2011/04/cribado_de_cervix_comunidad-de-madrid1.pdf. (Consultado 21-9-2013).
24. Disponible en: http://www.murciasalud.es/recursos/ficheros/266164-PIAM_2012.pdf. (Consultado 21-9-2013).
25. Disponible en: http://www.navarra.es/NR/rdonlyres/ED7-0315-52B9-4C63-B30C-8CD90D2424D2/146349/EvaluaciondelPlandeSaludde1991.pdf. (Consultado 27-9-2013).
26. Disponible en: http://www.osakidetza.euskadi.net/r85-gkgnrl00/es/contenidos/informacion/deteccion_cancer/es_cancer/cervix.html. (Consultado 20-9-2013).
27. Pérez-Gomez B, Martínez C, Navarro C, Franch P, Galceran J, Marcos-Gragera R. The moderate decrease in invasive cervical cancer incidence rates in Spain (1980-2004): limited success of opportunistic screening? Ann Oncol. 2010;21 Suppl 3:iii61-8.
28. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon: International Agency for Research on Cancer; 2004.
29. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol. 2007;18:1708-15.
30. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
31. European Union. Council recommendation of 2 December 2003 on cancer screening. 2003/878/EC. Bruselas; 2003.
32. Vaccarella S, Franceschi S, Engholm G, Lonnberg S, et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014. doi: 10.1038/bjc.2014.
33. Lynge E, Tornberg S, von KL, Segnan N, van Delden JJ. Determinants of successful implementation of populationbased cancer screening programmes. Eur J Cancer. 2012;48:743-8.
34. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann Oncol. 2010;21:448-58.
35. Division of Cancer Prevention and Control, National Center for Disease Prevention and Health Promotion Centers for Disease Control and Prevention. Cervical Cancer. Disponible en: http://www.cdc.gov/cancer/cervical/
36. Habbema D, De K, I, Brown ML. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q. 2012;90:5-37.
37. US Preventive Services Task Force (USPSTF). Screening for Cervical Cancer, Recomendations and Rationale. Disponible en: www.ahrq.gov
38. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14:677-86.
39. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess. 1999;3:i-196.
40. Wright TC Jr., Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-9.
41. Walker P. The English National Health Service Cervical Screening Programme-approach to new technologies and quality assurance. J Low Genit Tract Dis. 2005;9:118-23.
42. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla PP, Naldoni C, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007;335:28.
43. Ronco G, van BM, Becker N, Chil A, Fender M, Giubilato P, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer. 2009;45:2659-70.
44. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88-99.
45. Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme. Eur J Cancer. 1993;29A Suppl 4:S1-38.
46. European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. Luxembourg: Office for Official Publications of the European Communities; 2008. p. 1-291.
47. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-42.
48. De Kok I, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012;344:e670.
49. Castanon A, Landy R, Sasieni P. How much could primary human papillomavirus testing reduce cervical cancer incidence and morbidity? J Med Screen. 2013;20:99-103.
50. Adriaensen WJ, Mathei C, Buntinx FJ, Arbyn M. A framework provided an outline toward the proper evaluation of potential screening strategies. J Clin Epidemiol. 2013;66:639-47.
51. Dans LF, Silvestre MA, Dans AL. Trade-off between benefit and harm is crucial in health screening recommendations. Part I: general principles. J Clin Epidemiol. 2011;64:231-9.
52. Harris R. Overview of screening: where we are and where we may be headed. Epidemiol Rev. 2011;33:1-6.
53. Silvestre MA, Dans LF, Dans AL. Trade-off between beneffit and harm is crucial in health screening recommendations. Part II: evidence summaries. J Clin Epidemiol. 2011;64:240-9.
54. Freeman HP, Chu KC. Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment. Surg Oncol Clin N Am. 2005;14:655-69.
55. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, et al. Cervical cancer prevention: new tools and old barriers. Cancer. 2010;116:2531-42.
56. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and metaanalysis. Prev Med. 2007;45:93-106.
57. Wilson JM, Jungner G. Principles and practice of screening for disease. Public Health Papers. 1968;34:1-163.
58. Diario Official de la Unión Europea L327/34. 2014.
59. Arbyn M, Van OH, Lynge E, Micksche M, Faivre J, Jordan J. European Commission's proposal for a council recommendation on cancer screening. BMJ. 2003;327: 289-90.
60. Cortés J. Estrategias de cribado del cáncer de cuello uterino. Prog Obstet Ginecol. 2005;48:228-30.
61. Adab R, McGhee S, Hedley A. Screening and mortality from cervical cancer. Study shows importance of centralised organisation in screening. BMJ. 1999;319:642-3.
62. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 1999;318:904-8.
63. Von Karsa L, Anttila A, Ronco G, Ponti A, Malila N, Arbyn M, et al. Cancer screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening. First Report. Lyon: International Agency for Research on Cancer; 2013.
64. Anttila A, Ronco G. Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer. 2009;45:2685-708.
65. Díaz M, de San José S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer. 2010;46:2973-85.
66. Moscicki AB, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14:73-80.
67. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127:805-15.
68. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet.Gynecol. 2009;113:18-25.
69. Wright TC Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11:201-22.
70. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer. 1997;71:159-65.
71. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet.Gynecol. 2003;188:1383-92.
72. Castle PE, Bulten J, Confortini M, Klinkhamer P, Pellegrini A, Siebers AG, et al. Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials. BJOG. 2010;117:1067-73.
73. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst. 2011;103:1387-96.
74. Koss LG. Cytology. Accuracy of diagnosis. Cancer. 1989;64: 249-52.
75. Van der Graaf Y, Vooijs GP, Gaillard HL, Go DM. Screening errors in cervical cytologic screening. Acta Cytol. 1987;31:434-8.
76. Akamatsu S, Kodama S, Himeji Y, Ikuta N, Shimagaki N. A comparison of liquid-based cytology with conventional cytology in cervical cancer screening. Acta Cytol. 2012;56:370-4.
77. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167-77.
78. Davey E, D'Assuncao J, Irwig L, Macaskill P, Chan SF, Richards A, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ. 2007;335:31.
79. De Bekker-Grob EW, de Kok IM, Bulten J, van Rosmalen J, Vedder JE, Arbyn M, et al. Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis. Cancer Causes Control. 2012;23:1323-31.
80. Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, et al. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer. 1999;87:48-55.
81. Monsonego J, Autillo-Touati A, Bergeron C, Dachez R, Liaras J, Saurel J, et al. Liquid-based cytology for primary cervical cancer screening: a multi-centre study. Br J Cancer. 2001;84:360-6.
82. Pan QJ, Hu SY, Zhang X, Ci PW, Zhang WH, Guo HQ, et al. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. Cancer Cytopathol. 2013;121:473-82.
83. Sigurdsson K. Is a liquid-based cytology more sensitive than a conventional Pap smear? Cytopathology. 2013;24:254-63.
84. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155: 687-97.
85. Wright TC Jr., Stoler MH, Behrens CM, Sharma A, Sharma K, Apple R. Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int J Cancer. 2014;134:1835-43.
86. Alves VA, Bibbo M, Schmitt FC, Milanezi F, Longatto FA. Comparison of manual and automated methods of liquid based cytology. A morphologic study. Acta Cytol. 2004;48: 187-93.
87. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess. 2004;8:iii, 1-iii, 78.
88. Eversole GM, Moriarty AT, Schwartz MR, Clayton AC, Souers R, Fatheree LA, et al. Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134:331-5.
89. Tambouret RH. The evolution of the Papanicolaou smear. Clin Obstet Gynecol. 2013;56:3-9.
90. Joste N, Gober-Wilcox J. The modern cytology laboratory: moving beyond the Pap test. Obstet Gynecol Clin North Am. 2013;40:199-210.
91. Dalla Palma P, Moresco L, Giorgi RP. Health technology assessment of computer-assisted pap test screening in Italy. Acta Cytol. 2013;57:349-58.
92. Papillo JL, St John TL, Leiman G. Effectiveness of the ThinPrep Imaging System: clinical experience in a low risk screening population. Diagn Cytopathol. 2008;36:155-60.
93. Heard T, Chandra A, Culora G, Gupta SS, Herbert A, Morgan M. Use of the ThinPrep Imaging System for internal quality control of cervical cytology. Cytopathology. 2013;24: 246-53.
94. Halford JA, Batty T, Boost T, Duhig J, Hall J, Lee C, et al. Comparison of the sensitivity of conventional cytology and the ThinPrep Imaging System for 1, 083 biopsy confirmed highgrade squamous lesions. Diagn Cytopathol. 2010;38:318-26.
95. Thrall MJ, Russell DK, Bonfiglio TA, Hoda RS. Use of the ThinPrep Imaging System does not alter the frequency of interpreting Papanicolaou tests as atypical squamous cells of undetermined significance. Cytojournal. 2008;5:10.
96. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1-27.
97. Juste B, Miro R, Jambrina A, Diez S, Campayo JM, Santos A, et al. Comparison between transmission and scattering spectrum reconstruction methods based on EPID images. Conf Proc IEEE Eng Med Biol Soc. 2013;1640-3.
98. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516-20.
99. Lacruz C. Citología de las lesiones intraepiteliales escamosas. En: Lacruz C, Fariña J, eds. Citología ginecológica. De Papanocilau a Bethesda. Madrid: Editorial Complutense; 2003. p. 65-87.
100. Lacruz C, Vilaplana E. Citología endocervical. En: Lacruz C, Fariña J, eds. Citología ginecológica. De Papanocilau a Bethesda. Madrid: Editorial Complutense; 2003. p. 115-36.
101. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.
102. Cortés J, Xercavins J, Garrido R, Miranda P, Ramón y Cajal JM, Velasco J, et al. Conocimientos y adherencia a las nuevas recomendaciones de la SEGO para la prevención del cáncer de cuello de útero por parte de los ginecólogos españoles en la práctica diaria. Prog Obstet Ginecol. 2012;55:153-64.
103. Torne A, Fuste P, Rodríguez-Carunchio L, Alonso I, del PM, Nonell R, et al. Intraoperative post-conisation human papillomavirus testing for early detection of treatment failure in patients with cervical intraepithelial neoplasia: a pilot study. BJOG. 2013;120:392-9.
104. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for cervical cancer: A decision analysis for the US Preventive Services Task Force. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK92546/
105. Rebolj M, Helmerhorst T, Habbema D, Looman C, Boer R, van RJ, et al. Risk of cervical cancer after completed posttreatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ. 2012;345:e6855.
106. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91:530-6.
107. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619-31.
108. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med. 2008;168:1881-9.
109. Carozzi FM, Confortini M, Cecchini S, Bisanzi S, Cariaggi MP, Pontenani G, et al. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer. 2005;105:2-7.
110. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004;122:238-45.
111. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer. 2005;92:1800-2.
112. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
113. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-72.
114. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-72.
115. Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, et al. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol. 2005;124:716-21.
116. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-97.
117. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del MA, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-57.
118. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804.
119. Wang SS, Sherman ME, Hildesheim A, Lacey JV, Jr., Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004;100: 1035-44.
120. Castellsague X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-15.
121. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524-32.
122. Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can J Public Health. 2013;104:e159-66.
123. Wu X, Matanoski G, Chen VW, Saraiya M, Coughlin SS, King JB, et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer. 2008;113:2873-82.
124. Fox J, Remington P, Layde P, Klein G. The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am J Obstet Gynecol. 1999;180:1104-9.
125. Pearce KF, Haefner HK, Sarwar SF, Nolan TE. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. N Engl J Med. 1996;335:1559-62.
126. Piscitelli JT, Bastian LA, Wilkes A, Simel DL. Cytologic screening after hysterectomy for benign disease. Am J Obstet Gynecol. 1995;173:424-30.
127. Videlefsky A, Grossl N, Denniston M, Sehgal R, Lane JM, Goodenough G. Routine vaginal cuff smear testing in posthysterectomy patients with benign uterine conditions: when is it indicated? J Am Board Fam Pract. 2000;13:233-8.
128. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst. 2009;101:721-8.
129. Soutter WP, Butler JS, Tipples M. The role of colposcopy in the follow up of women treated for cervical intraepithelial neoplasia. BJOG. 2006;113:511-4.
130. NHS. Colposcopy and programme management: guidelines for NHS cervical screening program. 2a ed. NHS Cancer Screening Programmes; 2010.
131. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20:2337-44.
132. Stuardo V, Agusti C, Godinez JM, Montoliu A, Torne A, Tarrats A, et al. Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer. PLoS One. 2012;7:e47755.
133. Videla S, Darwich L, Canadas MP, Paredes R, Tarrats A, Castella E, et al. Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology. J Acquir Immune Defic Syndr. 2009;50:168-75.
134. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207.
135. Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA. 2012;308:362-9.
136. Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012;30 Suppl 5:F168-74.
137. Roccio M, Dal BB, Gardella B, Carrara M, Gulminetti R, Mariani B, et al. HPV infection and intraepithelial lesions: comparison between HIV positive and negative women. Curr HIV Res. 2012;10:614-9.
138. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 7:H1-31.
139. Leinonen MK, Nieminen P, Lonnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789.
140. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-88.
141. Rijkaart DC, Berkhof J, Rozendaal L, Van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78-88.
142. Schiffman M, Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med. 2013;369:2324-31.
143. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013;17:S56-63.
144. Del Pino M, Torne A, Alonso I, Mula R, Masoller N, Fuste V, et al. Colposcopy prediction of progression in human papillomavirus infections with minor cervical lesions. Obstet Gynecol. 2010;116:1324-31.
145. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-6.
146. Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol. 2014;210:474.e1-7.
147. Qiao YL, Jeronimo J, Zhao FH, Schweizer J, Chen W, Valdez M, et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer. 2014;134:2891-901.
148. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr., Cuzick J. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208:184.
149. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-9.
150. Twiggs LB, Hopkins M. High-risk HPV DNA testing and HPV-16/18 genotyping: what is the clinical application? J Low Genit Tract Dis. 2011;15:224-30.
151. Gage JC, Schiffman M, Solomon D, Wheeler CM, Castle PE. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. Cancer Epidemiol Biomarkers Prev. 2010;19:1668-74.
152. Gage JC, Duggan MA, Nation JG, Gao S, Castle PE. Comparative risk of high-grade histopathology diagnosis after a CIN 1 finding in endocervical curettage versus cervical biopsy. J Low Genit Tract Dis. 2013;17:137-41.
153. Cattani P, Siddu A, D'Onghia S, Marchetti S, Santangelo R, Vellone VG, et al. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J Clin Microbiol. 2009;47:2136-41.
154. Keegan H, Mc IJ, Pilkington L, Gronn P, Silva I, Karlsen F, et al. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods. 2009;155:61-6.
155. Liu TY, Xie R, Luo L, Reilly KH, He C, Lin YZ, et al. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples. J Virol Methods. 2014;196:120-5.
156. Pérez Castro S, Iñarrea Fernández A, Lamas González MJ, Sarán Díez MT, Cid Lama A, Álvarez Martín MJ, et al. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA. J Med Virol. 2013;85:1063-8.
157. Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT, Daalmeijer NF, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer. 2011;129:2218-25.
158. Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008;9:937-45.
159. Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013;14:168-76.
160. Roelens J, Reuschenbach M, von Knebel DM, Wentzensen N, Bergeron C, Arbyn M. p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and metaanalysis. Cancer Cytopathol. 2012;120:294-307.
161. Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol. 2010;134:12-21.
162. Dona MG, Vocaturo A, Giuliani M, Ronchetti L, Rollo F, Pescarmona E, et al. p16/Ki-67 dual staining in cervicovaginal cytology: correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy. Gynecol Oncol. 2012;126:198-202.
163. Edgerton N, Cohen C, Siddiqui MT. Evaluation of CINtec PLUS(R) testing as an adjunctive test in ASC-US diagnosed SurePath(R) preparations. Diagn Cytopathol. 2013;41:35-40.
164. Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013;105:1550-7.
165. Loghavi S, Walts AE, Bose S. CINtec(R) PLUS dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol. 2013;41:582-7.
166. Ordi J, Sagasta A, Munmany M, Rodríguez-Carunchio L, Torne A, del Pino M. Usefulness of p16/Ki67 immunostaining in the triage of women referred to colposcopy. Cancer Cytopathol. 2014;122:227-35.
167. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol. 2011;121:505-9.
168. Schmidt D, Bergeron C, Denton KJ, Ridder R. p16/ki-67 dualstain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011;119:158-66.
169. Waldstrom M, Christensen RK, Ornskov D. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol. 2013;121:136-45.
170. Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18:4154-62.
171. Zappacosta R, Caraceni D, Ciccocioppo L, Rotondo T, Capanna S, Gatta DM, et al. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme. Gynecol Oncol. 2013;128:427-32.
172. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136:1266-97.
173. Arbyn M, Rebolj M, De Kok IM, Fender M, Becker N, O'Reilly M, et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer. 2009;45:2671-8.
174. Simonella L, Canfell K. The impact of a two-versus threeyearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England. Cancer Causes Control. 2013;24:1727-36.
175. Kim JJ, Leung GM, Woo PP, Goldie SJ. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. J Public Health (Oxf). 2004;26:130-7.
176. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst. 2008;100:308-20.
177. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-23.
178. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Costeffectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer. 2012;106:1571-8.
179. Bornstein J, Bentley J, Bosze P, Girardi F, Haefner H, Menton M, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2012;120:166-72.
180. Puig-Tintoré LM, Torné A, Ordi J, Galcerán J, Ferré J. Colposcopia digital en la neoplasia cervical intraepitelial. Correlación histológica y utilidad clínica. Prog Obstet Ginecol. 2001;44:490-6.
181. Torné A. Colposcopia digital en las lesiones premalignas de cuello uterino. Morfometría y análisis de imagen. Tesis doctoral. Barcelona: Universitat de Barcelona; 2000.
182. Underwood M, Arbyn M, Parry-Smith W, De Bellis-Ayres S, Todd R, Redman CW, et al. Accuracy of colposcopy-directed punch biopsies: a systematic review and meta-analysis. BJOG. 2012;119:1293-301.
183. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006;108:264-72.
184. Puig-Tintoré LM. Prevención del cáncer cervical: Vacunación y colposcopia. En: Puig-Tintoré l, dir. Curso de formación continuada en prevención del cancer cervical, vacunación y colposcopia. Madrid: Edimsa; 2011. p. 31-78.
185. Guimera N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M, et al. The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol. 2013;37:1299-310.
186. Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127:335-7.
187. Ordi J, Puig-Tintore LM, Torne A, Sanz S, Esteve R, Romagosa C, et al. Contribution of high risk human papillomavirus testing to the management of premalignant and malignant lesions of the uterine cervix. Med Clin (Barc). 2003;121: 441-5.
188. Ordi J, Alonso I, Torne A, Esteve R, Sierra E, Campo E, et al. Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test? Gynecol Oncol. 2005;99:313-9.
189. Ramírez-Hidalgo A, Musset-Biarnes M, Vilamala-Muns M, Laso-Pérez E, Serrano-Munne L, Aameda-Quitllet F. Hybrid capture 2 high-risk human papillomavirus test: should "grey zone" results justify repeating the test? Anal Quant Cytol Histol. 2013;35:152-6.
190. Wiwanitkit V. Cervista HPV HR test kit in cervical cancer screening. J Low Genit Tract Dis. 2013;17:99.
191. Herráez-Hernández E, Preda O, Alonso S, Pardo RS, Olmo A. Detection and genotyping of human Papillomavirus DNA in formalin-fixed paraffin-embedded specimens with the HPV directfiow CHIP System. Open Virol J. 2013;7:91-5.
192. Lloveras B, Gómez S, Alameda F, Bellosillo B, Mojal S, Muset M, et al. Correction: HPV testing by cobas HPV test in a population from Catalonia. PLoS One. 2013;8.
193. Brainard JA, Birdsong GG, Elsheikh TM, Hartley DA, Naik K, Neal MH, et al. Prospective and retrospective review of gynecologic cytopathology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 2. Arch Pathol Lab Med. 2013;137:175-82.
194. Elsheikh TM, Kirkpatrick JL, Cooper MK, Johnson ML, Hawkins AP, Renshaw AA. Increasing cytotechnologist workload above 100 slides per day using the ThinPrep imaging system leads to significant reductions in screening accuracy. Cancer Cytopathol. 2010;118:75-82.
195. Manrique EJ, Souza NL, Tavares SB, Albuquerque ZB, Zeferino LC, Amaral RG. Analysis of the performance of 100% rapid review using an average time of 1 and 2 minutes according to the quality of cervical cytology specimens. Cytopathology. 2011;22:195-201.
196. Crothers BA, Jones BA, Cahill LA, Moriarty AT, Mody DR, Tench WD, et al. Quality improvement opportunities in gynecologic cytologic-histologic correlations: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 4. Arch Pathol Lab Med. 2013;137:199-213.
197. Bulten J, Horvat R, Jordan J, Herbert A, Wiener H, Arbyn M. European guidelines for quality assurance in cervical histopathology. Acta Oncol. 2011;50:611-20.
198. Azara CZ, Manrique EJ, ves de Souza NL, Rodrigues AR, Tavares SB, Amaral RG. External quality control of cervical cytopathology: interlaboratory variability. Acta Cytol. 2013;57:585-90.
199. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47:864-71.
200. Scapulatempo C, Fregnani JH, Campacci N, Possati-Resende JC, Longatto-Filho A. The significance of augmented highgrade squamous intraepithelial lesion detection on pap test examination: partial results from the RODEO study team. Acta Cytol. 2013;57:489-94.
201. Moss EL, Arbyn M, Dollery E, Leeson S, Petry KU, Nieminen P, et al. European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol. 2013;170:255-8.
202. Redman CWE. Minimum Standards for Colposcopy Training. Disponible en: http://www.e-f-c.org/pages/education/minimum-standards-for-colposcopy-training.php
203. Rodríguez-Mías NL, Cortés J, Xercavins J, Lailla JM. Current situation: lower genital tract pathology and colposcopy training in Spanish gynecology and obstetrics residents. J Low Genit Tract Dis. 2013;17:12-6.
204. Aznar F, Royo P, Rodríguez, D, Martínez R, Orensanz I, Bajo Arenas JM. Calidad de la formación especializada en patología del tracto genital inferior en las unidades docentes de España. XIX Congreso AEPCC. Comunicacion C06-1; 2007.
205. Cortés J. Acreditación en colposcopia. Boletín AEPCC. 2006;19:9-10.
206. Coloma F, Costa S, Sanz I. Control de calidad en colposcopia. XXIII Congreso AEPCC; 2011.
207. Leeson SC, Alibegashvili T, Arbyn M, Bergeron C, Carriero C, Mergui JL, et al. The future role for colposcopy in Europe. J Low Genit Tract Dis. 2014;18:70-8.
208. Petry KU, Luyten A, Scherbring S. Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol. 2013;128:282-7.
209. Moss EL, Arbyn M, Dollery E, Leeson S, Petry KU, Nieminen P, et al. European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol. 2013;170:255-8.
210. Nam K, Chung S, Kwak J, Cha S, Kim J, Jeon S, et al. Random biopsy after colposcopy-directed biopsy improves the diagnosis of cervical intraepithelial neoplasia grade 2 or worse. J Low Genit Tract Dis. 2010;14:346-51.
211. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004;191:430-4.
212. Ismail SM, Colclough AB, Dinnen JS, Eakins D, Evans DM, Gradwell E, et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ. 1989;298:707-10.
213. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-5.
214. Acevedo A, Lorenzo S, Pinedo F. Sistemas de gestión de la calidad. Libro blanco de la Anatomía Patológica en España. Zaragoza: Sociedad Española de Anatomía Patológica; 2009. p. 67-90.
215. Malpica A, Matisic JP, Niekirk DV, Crum CP, Staerkel GA, Yamal JM, et al. Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues. Gynecol Oncol. 2005;99:S38-52.
216. Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol. 2010;34: 1077-87.
217. Guo M, Baruch AC, Silva EG, Jan YJ, Lin E, Sneige N, et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol. 2011;135:212-20.
218. Benevolo M, Terrenato I, Mottolese M, Marandino F, Muti P, Carosi M, et al. Comparative evaluation of nm23 and p16 expression as biomarkers of high-risk human papillomavirus infection and cervical intraepithelial neoplasia 2(+) lesions of the uterine cervix. Histopathology. 2010;57: 580-6.
219. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133:395-406.
220. Dijkstra MG, Heideman DA, de Roy SC, Rozendaal L, Berkhof J, van Krimpen K et al. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol. 2010;63:972-7.
221. Horn LC, Reichert A, Oster A, Arndal SF, Trunk MJ, Ridder R, et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2008;32:502-12.
222. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1389-99.
223. McCluggage WG. Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology. 2007;39:97-111.
224. Negri G, Vittadello F, Romano F, Kasal A, Rivasi F, Girlando S, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch. 2004;445:616-20.
225. Ordi J, García S, del Pino M, Landolfi S, Alonso I, Quinto L, et al. p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women. Int J Gynecol Pathol. 2009;28:90-7.
226. Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS, Wallin KL. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res. 2004;10:2407-14.
227. Hariri J, Oster A. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol. 2007;26:223-8.
228. Kong CS, Balzer BL, Troxell ML, Patterson BK, Longacre TA. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol. 2007;31:33-43.